Institutional Biosafety Committee

CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: May 15, 2026
Time: 10:30 AM – 12:00 PM
Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	☒	13. NCEZID/DCLSR2	☒
2. NCIRD/DVD	☒	14. IOD/OLSS3	☐
3. NCEZID/DHCPP1	☒	16. NCEZID/DCLSR3	☐
4. IOD/OLSS1	☒	17. NCEZID/OD	☐
5. OCOO/OSSAM/OHC	☐	18. IOD/OLSS4	☒
6. NCEZID/DVBD2	☒	19. NCHHSTP/DHP2	☒
7. IOD/OLSS2	☒	20. Outside Member/Atlanta1	☒
8. NCHHSTP/DHP1	☐	21. Outside Member/Atlanta2	☒
9. NCHHSTP/DTE	☐	22. Outside Member/Fort Collins	☒
10. NCIRD/ID	☐	23. Outside Member/Puerto Rico	☐
11. NCIRD/CORVD	☒	24. CDC/GHC/OD	☐
12. NCEZID/DCLSR1	☒	**Visitor(s)**	**5**

Agenda

1. **10:33 am EST-** Welcome and quorum confirmation
2. Review and approval of **April 17, 2026** Meeting Minutes
3. Review of IBC registrations:
    1) IBC-2025-313 Amendment
    2) IBC-2026-314 Amendment
    3) IBC-2026-315 Renewal
4. Other Business

Review of IBC Registrations

1. **IBC-2025-313 Renewal**
   General Project Description: Influenza virus causes severe respiratory disease with significant mortality. The proposed studies are aimed to 1) understand how the virus interacts with the host cells and contribute to disease in humans; 2) develop influenza candidate vaccine viruses (CVVs). To this end, we will use recombinant DNA technology to produce viruses containing genes from influenza virus of human or animal origin, and subsequently test them in the test tube and in laboratory animals. These studies will provide information necessary to develop plans and design interventions for early detection and mitigation of an eventual influenza pandemic.
   Approximate percentage of the viral genome used: >2/3
   Applicable Sec of NIH Guidelines: III-D-2, III-D-3, III-D-4, III-D-7
   Required biological containment level for the work to be implemented: BSL-3E
   General Points Discussed:
   - **Section 2.9:** Should be “no” and text on 2.9a/b/c/d should be deleted.

- **Section 2.12:** First sentence in 1.3 states this protocol covers CVV work for all H1-18 HA and N1-11 NA, which includes RG2 and RG3 viruses. However, only III-D-3-b is selected which only covers RG3 viruses. III-D-3-a also needs to be selected or the sentence in section 1.3 needs editing/deleting. III-F-8 should be checked to cover cloning.

Committee Action: Approved with changes

2. **IBC-2025-314 Renewal**
   General Project Description: Infectious clones of the Sabin live attenuated oral poliovirus vaccines (OPVs) including Sabin type 1, Sabin type 2 and Sabin type 3, and Salk inactivated poliovirus vaccines (IPV) - killed wild polioviruses (WPVs) including Mahoney (type 1), MEF-1 (type 2), and Saukett (type 3) were engineered via codon deoptimization for the goal of developing safer, more genetically stable vaccine candidates. Preferred codons were replaced in the viral genome with synonymous unpreferred codons ("codon deoptimization") to confer a stable attenuated phenotype. Additional, well-characterized attenuating modifications described in the literature were incorporated into a subset of our clones. Infectious virus will be tested for replicative fitness, antigenicity, immunogenicity, and genetic stability in cell culture models to assess their pre-clinical potential as new vaccine candidates needed to support global polio eradication.
   Approximate percentage of the viral genome used: >2/3
   Applicable Sec of NIH Guidelines: III-D-1, III-D-2, III-D-3
   Required biological containment level for the work to be implemented: BSL-2, BSL-3
   General Points Discussed:
   - **Section 3**: In the entry "RDNA/RNA Host-836", please indicate in Section 3.2 that *E. coli* K-12 strain is used for the study. In the poliovirus section (RDNA/RNA Host-835), answers to 3.3d and 3.3e are needed.

   Committee Action: Approved with changes

3. **IBC-2025-315 Renewal**
   General Project Description: The goal of this project is to develop a reverse genetic system for Arenaviruses in order to determine site-specific molecular determinants that lead to high pathogenicity in humans and further develop viral replicon particle (VRP) vaccines.
   Approximate percentage of the viral genome used: >2/3
   Applicable Sec of NIH Guidelines: III-D-1, III-D-2, III-D-3, III-D-4
   Required biological containment level for the work to be implemented: BSL-2, BSL-4
   General Points Discussed:
   - **Section 2.12:** Please select III-F8 for *E. coli* work.

   Committee Action: Approved with changes

Other Business

- Briefing on Laboratory Incident Investigation (4/14/2026)
  - Presented by IBC Biosafety Officer.
  - A formal investigation report has been sent to NIH OSP.
- Introduction of IBC Animal SMEs
  - IBC Animal SME Responsibilities listed in the 2026 IBC Charter:

- Performs a pre-review of IBC submissions that involve animal work, in collaboration with the IBC Chair, Co-Chair, and BSO.
- Ensures appropriate physical and biological containment for research involving recombinant or synthetic nucleic acid molecules in animals, consistent with Section III of the NIH Guidelines.
- Serves as IBC liaison to CDC IACUC.
- Verifies through the IBC Administrator that an active IBC registration exists for the animal species involving recombinant or synthetic nucleic acid molecules proposed in an IACUC protocol.
- With help from the IBC and IACUC Administrators, confirm that the IBC registration(s) and IACUC protocol(s) referenced in each submission are accurate and complete.

- Discussion on Cross Review
  - Committee deliberated on the Cross Review section in PULSE.
  - Cross review section is deemed necessary for quality purposes and may be re-named in the future for clarification.
- Committee Rapporteur (CR) discussion
- Meeting adjourned at 11:38 AM

REYNOLDS M. SALERNO -S

Digitally signed by REYNOLDS M. SALERNO -S
Date: 2026.08.10 10:36:58 -04'00'

Reynolds M Salerno, PhD
Director, Office of Laboratory Systems and Response